Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 6, 2008, Pages 867-872

  Singh, K ^a   Dickinson, L ^b   Chaikan, A ^b   Back, D ^b   Fletcher, C ^a   Pozniak, A ^a   Moyle, G ^a   Nelson, M ^a   Gazzard, B ^a   Herath, D ^c   Boffito, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; OMEPRAZOLE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CROSS-OVER STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEADACHE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; RITONAVIR; SAQUINAVIR;

EID: 43949122963     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100375     Document Type: Article

References (30)

1. Gazzard, B. et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 7, 487-503 (2006).
2. Boffito, M. et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir. Ther. 10, 469-477 (2005).
3. Moyle, G.J. & Back, D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2, 105-113 (2001).
4. Luber, A. et al. Survey of medication used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART. In 7th Int. Cong. Drug Therapy HIV Infect., Glasgow, UK. Abstract no. P294.
5. Burgos, A. & Garrido, J. Use of acid reducing agents among HIV infected patients receiving antiretrovirals in Spain. In 10th Eur. AIDS Conf., Dublin, Ireland. Abstract no. 4.3/5.
6. van Lunzen, J., Liess, H., Arasteh, K., Walli, R., Daut, B. & Schurmann, D. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy. HIV Med. 8, 220-225 (2007).
7. Agarwala, S. et al. Pharmacokinetic (PK) effect of omeprazole (OMP) on atazanavir (ATV) with ritonavir (RTV) in healthy subjects. In 12th Conf. Retrovir. Oppor. Infect., Boston, MA, USA. Abstract no. 658.
8. Bertz, R. et al. Effect of omeprazole 20mg daily on the availability of multiple-dose atazanavir with ritonavir in healthy subjects. In 8th Int. Workshop Clin. Pharmacol. HIV Ther., Budapest, Hungary. Abstract no. 66.
9. Agarwala, S.E.T. et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. In 6th Int. Workshop Clin. Pharmacol. HIV Ther., Quebec City, Quebec, Canada. Abstract no. 11.
10. van Heeswijk, R.S.J. et al. The pharmacokinetic interactions between tipranavir/ritonavir 500/200mg bid (TPV/r) and atorvastatin, antacid, and CYP3A4 in healthy adult volunteers. In 5th Int. Workshop Clin. Pharmacol. HIV Ther., Rome, Italy. Abstract no. 35.
11. la Porte, C. et al. The effect of omeprazole, food and formulation on the pharmacokinetics of tipranavir coadministered with ritonavir (TPV/r). In 8th Int. Workshop Clin. Pharmacol. HIV Ther., Budapest, Hungary. Abstract no. 59.
12. min and AUC were similar to historical control when IDV administered with 200 mg RTV. In 43rd Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, USA. Abstract no. A-1611.
13. Sekar, V.J. et al. Pharmacokinetic interactions between TMC114/r and omeprazole or ranitidine in HIV-negative healthy volunteers. Antimicrob. Agents Chemother. 51, 958-961 (2007).
14. Klein, C. et al. Lack of effect of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir tablet. In 13th Conf. Retrovir. Oppor. Infect., Denver, CO, USA. Abstract no. 578.
15. Boffito, M. et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J. Antimicrob. Chemother. 50, 1081-1084 (2002).
16. Kakuda, T.N. & Falcon, R.W Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacotherapy 26, 1060-1068 (2006).
17. Winston, A. et al. Effect of omeprazole on the PK of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 20, 1401-1406 (2006).
18. trough concentrations between HIV-infected individuals and healthy volunteers administered saquinavir mesylate 500 mg film-coated tablets (1,000/100 mg twice daily). In 7th Int. Workshop Clin. Pharmacol. HIV Ther., Lisbon, Portugal. Abstract no. 60.
19. Invirase®. Saquinavir mesylate summary of product Characteristics. Roche Pharmaceuticals, Roche Laboratories, Nutley, NJ, USA, November (2005).
20. Ko, J.W., Sukhova, N., Thacker, D., Chen, P. & Flockhart, D.A. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab. Dispos. 25, 853-862 (1997).
21. Pauli-Magnus, C., Rekersbrink, S., Klotz, U. & Fromm, M.F. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. 364, 551-557 (2001).
22. Furuta, S. et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 31, 1-10 (2001).
23. Owen, A., Chandler, B. & Back, D.J. The implications of P-glycoprotein in HIV: friend or foe? Fundam. Clin. Pharmacol. 19, 283-296 (2005).
24. Janneh, O. et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, p-gp and BCRP. AIDS 19, 2097-2102 (2005).
25. Colombo, S. et al. Influence of ABCB1, ABCC1, ABCC2, ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet. Genomics 15, 599-608 (2005).
26. Huisman, M.T. et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16, 2295-2330 (2002).
27. Takahata, T. et al. Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates. Basic Clin. Pharmacol. Toxicol. 94, 252-256 (2004).
28. Furuta, T., Shirai, N., Sugimoto, M., Ohashi, K. & Ishizaki, T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5, 181-202 (2004).
29. Grub, S., Bryson, H., Goggin, T., Ludin, E. & Jorga, K. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur. J. Clin. Pharmacol. 57, 115-121 (2001).
30. Dickinson, L., Robinson, L., Tjia, J., Khoo, S. & Back, D. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 829, 82-90 (2005).